Verona Pharma is at an exciting stage of its development with data from the final part of its Phase I/II trial of RPL554 (multiple ascending dose – MAD – trial in COPD patients) due in the coming weeks. Ahead of this announcement we evaluate the significant potential upside of RPL554 as it continues its positive progress. As an illustration, our intrinsic value per share could increase from 7p to 28p if it successfully progresses to Phase III with a partner. We remain upbeat about Verona’s futur ....
